Relmada Therapeutics ( (RLMD) ) has shared an update.

Relmada Therapeutics Inc (RLMD) stock saw a decline, ending the day at $0.45 which represents a decrease of $-0.07 or -13.46% from the prior close of $0.52. The stock opened at $0.52 and touched a low ...

Mizuho has recently reduced Relmada Therapeutics Inc (RLMD) stock to Neutral rating, as announced on December 5, 2024, according to Finviz. Earlier, on September 17, 2024, Jefferies had raised the ...

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1 ...

Relmada Therapeutics , Inc. (NASDAQ:RLMD), a pharmaceutical company currently valued at $13.5 million, announced the appointment of Paul Kelly as Chief Operating Officer (COO) effective January 1, ...

Investing.com - Relmada Therapeutics (NASDAQ: RLMD) reported third quarter EPS of $-0.73, $0.18 better than the analyst estimate of $-0.91. Revenue for the quarter came in at... ByInvesting.com ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...

On Tuesday, Jefferies, a global investment banking firm, upgraded Relmada Therapeutics Inc (NASDAQ:RLMD) stock from Hold to Buy, significantly raising the price target to ...